Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The drug development enterprise is struggling. The development of new therapies is limited by high costs, slow progress, and a high failure rate, even in the late stages of development. Clinical trials are most commonly based on a “one population, one drug, one disease” strategy, in which the clinical trial infrastructure is created to test a single treatment in a homogeneous population.
This approach has been largely unsuccessful for multiple diseases, including sepsis, dementia, and stroke. Despite promising preclinical and early human trials, there have been numerous negative phase 3 trials of treatments for Alzheimer disease1 and more than 40 negative phase 3 trials of neuroprotectants for stroke.2 Effective treatments for such diseases will likely require combining treatments to affect multiple targets in complex cellular pathways and, perhaps, tailoring treatments to subgroups defined by genetic, proteomic, metabolomic, or other markers.3
Berry SM, Connor JT, Lewis RJ. The Platform TrialAn Efficient Strategy for Evaluating Multiple Treatments. JAMA. 2015;313(16):1619-1620. doi:10.1001/jama.2015.2316